Premium
Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging
Author(s) -
Soper John T.,
Berchuck Andrew,
ClarkePearson Daniel L.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910815)68:4<725::aid-cncr2820680410>3.0.co;2-1
Subject(s) - medicine , adjuvant therapy , stage (stratigraphy) , lymph node , surgery , ovarian carcinoma , omentectomy , carcinoma , hysterectomy , ovarian cancer , oncology , cancer , chemotherapy , paleontology , biology
Forty‐nine women with apparent Stage I and II ovarian carcinoma received intraperitoneal phosphate 32 as the only adjuvant therapy after primary surgery. In addition to bilateral salpingo‐oophorectomy, 40 (82%) had analysis of peritoneal cytology, and 35 (71%) underwent omentectomy. Random peritoneal biopsies and retroperitoneal lymph node sampling were not done in any of these patients. The overall and disease‐free survival rates were 86% and 75%, respectively, with no significant differences by stage, histologic grade, histologic type, or low‐risk versus high‐risk subsets recognized in patients who received comprehensive surgical staging. Seven (58%) of 12 patients had lymph node metastasis as the first site of recurrence, including two of three with late recurrences. Significant morbidity related to intraperitoneal chromic phosphate ( 32 P) occurred in one (2%) woman. These results emphasize the need for comprehensive surgical staging of women with apparent early ovarian carcinoma to aid in the selection of appropriate initial adjuvant therapy.